Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Up 156.9% in June

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 455,197 shares, a growth of 156.9% from the June 15th total of 177,209 shares. Based on an average trading volume of 444,373 shares, the days-to-cover ratio is presently 1.0 days. Approximately 46.8% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Bluejay Diagnostics currently has an average rating of “Sell”.

Bluejay Diagnostics Stock Performance

NASDAQ:BJDX traded down $0.07 during mid-day trading on Thursday, hitting $1.27. 381,814 shares of the stock were exchanged, compared to its average volume of 1,927,209. The stock has a market capitalization of $1.32 million, a price-to-earnings ratio of -0.11 and a beta of 0.88. The firm’s 50-day simple moving average is $2.66 and its 200 day simple moving average is $2.46. Bluejay Diagnostics has a fifty-two week low of $1.03 and a fifty-two week high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Insider Buying and Selling at Bluejay Diagnostics

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt purchased 64,047 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were acquired at an average price of $1.51 per share, for a total transaction of $96,710.97. Following the purchase, the insider owned 126,993 shares in the company, valued at approximately $191,759.43. The trade was a 101.75% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.